SCHOTT Pharma announces plans to solidify its footprint in the United States with the establishment of a cutting-edge facility in Wilson, North Carolina. This strategic move, supported by $21 million in state and local incentive awards, marks a significant milestone in SCHOTT Group’s expansion strategy in key growth markets.

With an emphasis on meeting the rising demand for advanced pharmaceutical containment solutions, SCHOTT Pharma will spearhead the production of prefillable polymer syringes vital for the storage and transportation of mRNA medications requiring deep-cold conditions. Additionally, the site will manufacture glass prefillable syringes tailored for GLP-1 therapies targeting diseases like diabetes and obesity. The project, slated to commence groundbreaking by the end of 2024, is anticipated to commence operations in 2027.

The Wilson facility is projected to add 401 high-quality jobs to the region and represents a total investment of $371 million. SCHOTT Pharma aims to triple its contribution of glass and polymer syringes to the U.S. market by 2030, aligning with the growing need for advanced medical delivery systems.

Andreas Reisse, CEO of SCHOTT Pharma, highlights the transformative impact of the new facility, stating, “As drug manufacturers increasingly rely on advanced biologic therapies, SCHOTT Pharma is committed to providing swift and efficient solutions to meet evolving market demands. The Wilson facility will not only bolster local employment but also strengthen the resilience of the pharmaceutical supply chain.”

The strategic location of Wilson County, coupled with its proximity to the Research Triangle area, underscores North Carolina's position as an ideal hub for biopharmaceutical innovation. Christopher Cassidy, President of SCHOTT North America, acknowledges the region's conducive environment for growth and innovation, emphasizing the company's commitment to addressing escalating demand for its premium solutions.

Senator Buck Newton of North Carolina commends SCHOTT Pharma's investment, affirming the state's pro-business policies and robust talent pool. He underscores the economic benefits SCHOTT’s presence will bring to Wilson County and the broader biopharma sector.

The establishment of the Wilson facility represents SCHOTT Pharma’s strategic response to growing market demands and underscores its commitment to advancing pharmaceutical innovation in the U.S. The company looks forward to leveraging local talent and resources to drive continued growth and success